Distinguishing Disease Control From Disease Modification in MG

In this episode, ‘Distinguishing Disease Control From Disease Modification in MG,’ the panel of neuromuscular experts explores the evolving distinction between disease control and disease modification in myasthenia gravis. Faculty discuss the traditional view of disease-modifying therapy as treatment that alters the underlying immune mechanism rather than providing transient symptomatic benefit. They note that many conventional and targeted immunotherapies modify disease activity while treatment is present, but the underlying autoimmune process may remain capable of reemerging when therapy is withdrawn.

The discussion then considers a more ambitious definition of disease modification based on whether treatment changes the longer-term trajectory of MG after therapy is stopped. The panel emphasizes that this degree of durable immunologic remission remains difficult to achieve with most currently available therapies. They contrast upstream strategies intended to influence antibody production with downstream approaches that can rapidly control pathogenic effects while slower mechanisms take effect. Rather than viewing these strategies as mutually exclusive, the faculty discuss how upstream and downstream therapies may be used together to achieve rapid clinical control while pursuing a more durable response.

The panel ultimately frames complete medication-free remission as an aspirational goal, while recognizing pharmacologic remission with well-controlled disease and minimal corticosteroid exposure as a more realistic objective for many patients.

The next episode in this series, ‘Understanding FcRn Inhibition and Pathogenic IgG Reduction in MG,’ features the panelists examining FcRn-mediated IgG recycling and how disruption of this pathway can rapidly reduce circulating pathogenic antibodies.